The SARAH trial was limited to high-risk patients, which the lead investigator said prevented unnecessary exposure to adverse ...
The FINEARTS-HF study included 46% women, showing finerenone's efficacy in reducing cardiovascular events in HFmrEF/HFpEF ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback